Graeme Chapman is an experienced industry solutions professional delivering digital transformation to healthcare and pharmaceutical organisations in the UK.
Graeme also has experience in Central Government, Retail Banking, Insurance, Manufacturing and Utilities.
Graeme holds a Masters degree in Engineering and post graduate qualifications in Management and Marketing.
Rupert is Head of Insight at uMotif and has lead analytics projects across many different industries including digital health, media, public sector and financial services. He has a wide range of experience covering technologies for data mining, visualisation and programming and has a passion for making complex data analysis accessible.
Health research is going through a period of rapid change driven by increased understanding that the patient needs to be seen as more than just a source of data. Rapid digitisation is helping to increase patient engagement around their healthcare and at a higher level become partners in the drive towards improved medications, and equally important ongoing collaborators all the way from clinical trials into the real world. This session will look at:
▪ The growing importance of Real World Evidence and why this will start to become a continuum flowing from the clinical trial process
▪ The growing importance of digital approaches as a technology foundation for research with examples from recent case studies in areas such as Parkinsons.
▪ The increase in the usage of patients own devices combined with sensors to drive both an individual's understanding of their health and to capture data for use in research
Attendees will leave the session understanding:
▪ An understanding how research is starting to be built around the patient, and what this patient-
centricity means for all players.
▪ How an engaged patient will help increase the quality of clinical research
▪ Insights gained from recent pivotal large scale direct to patient research in Parkinsons patients.
Dr David Lewis joined Patient Safety at Novartis in March 2007. He was EU QPPV from April 2009 then became Global Head of Pharmacovigilance Systems and Data Management. He has been Global Head of Pharmacovigilance since February 2011. Dr Lewis has experience of working in country affiliates and in a variety of global safety and risk management functions with both investigational and marketed products, as well as in roles concerned with systems and processes. Previous experience was gained at Shire Pharmaceuticals and at GSK. Dr Lewis is the author of papers on drug safety as well as research papers on neuropharmacology. He has a number of academic links, including being named Visiting Senior Fellow, Faculty of Health and Human Sciences, University of Hertfordshire. Dr Lewis is Project Coordinator for the WEB-RADR consortium @http://www.web-radr.eu. Outside of his scientific work Dave runs a smallholding and maintains an interest in retaining his advanced driving licence. He actively participates in various sports, having played cricket and hockey at representative level. He maintains that he will retire from competitive cricket when either of his sons, aged 24 and 26, end the season with a higher batting average and having taken more catches. Performances in 2016 have allowed him to look forward to playing again in the summer of 2017.
Gemma Estrada Bertan is an Executive with solid background in Clinical Research as well as in Science who is committed to reimagine Pharma companies by leveraging “digital” on behalf of patients, doctors, payers, partners and employees to make sustainable impact on healthcare.
Gemma is happy to bridge and integrate different cultural environments for transnational projects. Gemma has the ability to drive the vision, enhance performance and effectively frame problems when they arise. Gemma relate to all team members, build trust and create the right spirit that ultimately allows the project to thrive.
Currently, Gemma is Director Digital Health and technology at Ferrer, a privately owned pharmaceutical and chemical company headquartered in Barcelona. Previously, Gemma developed the Harrison Clinical Research operation (HCR) in Spain and was its Managing Director during 12 years. Following the merger of Synteract, Inc with HCR, Gemma grew into the position of Regional Director of South Europe, Israel and Latin America.
Gemma’s major professional achievement was the establishment of the legal and financial infrastructure to operate in Argentina and Spain where we enabled 11 years of continuous growth.
Past experience also includes managing the Barcelona Clinical Trials Platform (BCTP), a strategic instrument promoted by the Health Department of the Catalan Government to strengthen clinical research capacity in the region.
As a young professional Gemma was monitor and project manager at J. Uriach & Cía (1995-1997) and Sanofi (1997-2000), as well as a research fellow at the Universitat de Barcelona (1989-1991), at the New England Medical Center -Tufts university, Boston, MA, (1992-1994), and an invited researcher at the Academish Medish Centrum – Universitat van Amsterdam (1993).
With regards to publications Gemma has contributed 20 articles in peer review journals and non indexed magazines.
Gemma cultivate an active network of relationships across multiple organizations and academia.
Dr Elin Haf Davies has combined her career in paediatric health and her passion for sport and extreme adventure.
Elin Haf Davies began her career as a Paediatric Nurse at Great Ormond Street Children’s Hospital in London before going on to gain a PhD from University College London. After eight years of clinical experience Elin moved to research and spent six years managing clinical and academic drug trials, in metabolic, neurology, endocrinology and pain. Her PhD was based on the development of age-appropriate and disease specific biomarkers and clinical endpoints in neurometabolic, with a focus on ataxia and gait.
In 2007 Elin moved to work at the European Medicine Agency Paediatric Team where, amongst other projects she evaluated over a 100 Paediatric Investigation Plans of drug trials in children during her six years there.
In 2014 Elin founded aparito – a digital health social enterprise using wearable technology and smart phone apps to monitor patients remotely.
In her free time Elin has a passion for extreme adventure to raise money for charities close to her heart. In 2007-2008 she rowed across the 2600 miles across the Atlantic Ocean, raising £190,000 for metabolic research at Great Ormond Street Hospital. Money that funded a PhD project that identified the value of Vitamin B6 for managing neonatal seizures, an area that Elin is now actively supporting in her professional capacity.
In 2009 Elin was part of the first all female crew to ever row across the Indian Ocean. The 3500 miles took 78 days to complete, but secured a place for the girls in the 2011 Guinness Book of Records. The challenge also raised over £26,000 for Breast Cancer Care.
In 2012 Elin completed her hat-trick of oceans by sailing 6000 miles across the north Pacific, in 30 days. This time raising money for Noah’s Arch that aims to establish the first children’s hospital in Wales.
Elin’s adventures over the years have raised over £250,000 for charities. She has been acknowledged by the Welsh Assembly for Services to Wales, published an honest and gritty account of her experiences “On Tempestuous Seas”, and was selected to carry the 2012 Olympic Torch.
Dr. Petra Jantzer is a Managing Director in Accenture’s Life Science Organization.
Petra Jantzer is the CEO for LifeSciences in Germany, Austria, and Switzerland, responsible for Accenture’s global services to our Pharmaceuticals and MedTech clients based in this geography. Petra also leads our European Accelerated R&D Services, helping our clients across the world to bring cutting edge innovation to patients in need.
Petra has more than 20 years’ experience in R&D, both as a consultant in the (bio)pharmaceuticals sector and as a researcher. Petra combines profound industry and R&D knowledge, deep business process understanding, and more than a decade of C-level counseling experience to help clients (digitally) transform their businesses.
Petra holds a PhD in immunology and an honors degree in molecular biology.
Urvashi Prasad is a public policy specialist at NITI Aayog, the Indian Government’s premier think tank. She is also the founder of Every Voice, a platform that highlights the perspectives, needs, challenges and aspirations of people living in poverty in their own words. Urvashi was previously a Director at Operation ASHA, one of India’s largest tuberculosis control NGOs. She also led the health portfolio of the Michael & Susan Dell Foundation in India for five years. Urvashi is on the governing board of Partnership for TB Care & Control, the largest tuberculosis network in India. She completed her Bachelors in Genetics from University of Birmingham, UK, followed by a Masters in Bioscience Enterprise from University of Cambridge, UK and a Masters in Public Health from the London School of Hygiene & Tropical Medicine. Urvashi is passionate about gender-related and animal welfare issues. She is also a blogger and writes extensively for several platforms including the Huffington Post and Nextbillion.net.
Clinical efficacy trials in people are not always feasible or ethical, thus hampering the development and testing of countermeasures for lethal or permanently disabling toxic agents (e.g. chemical, biological, radiological or nuclear substances). This talk will give a quick overview of how the FDA Animal Efficacy Rule overcomes this problem and examples of life-saving animal models for emerging infectious diseases such as Ebola. Case study will be presented on collaboration between academic, non-profit, public and private sector organisations to combat recent emergencies such as Ebola and Zika.
Dr Maruthi Viswanathan is the Founder and Chief Executive Officer of a digital startup RxPrism Health Systems located in the Silicon Valley of India. A physician by education, Dr Maruthi is a dynamic visionary with international expertise in scientific education, medico-marketing communication, medical simulations, mobile applications, and innovative healthcare systems for patients and healthcare providers alike. Dr Maruthi has developed a unique 3-D software for scientific visualization and has several copyrights to his credit. An innovator par excellence, he has ideated, designed, and deployed a multitude of digital options for the top pharmaceutical companies worldwide.
Andrew Fried is IBM Life Sciences Leader for Europe.
Andrew helps clients address industry imperatives and save lives through the power of cognitive insights. He works with clients to advance the next generation of discovery and development, acting on insights to drive value, enhance relationships across the ecosystem and empowering people to make better decisions.
Prior to transferring to Europe in July 2015, Andrew was IBM’s Life Sciences Leader for China. While in China Andrew worked with many leading multi-national companies and several Chinese Life Sciences companies who were leaders in their respective segment.
Before joining IBM in 2000, Andrew had a successful 14-year career with a leading strategy consulting company. He graduated from Melbourne University with a Bachelor of Arts, and Monash University (Melbourne, Australia) with a Bachelor of Business. Andrew has a Masters of Business Administration from the International University of Japan and is a Fellow of the Financial Services Institute of Australasia. He was a three-term board member on a government enterprise with assets of over $350M. He was a founding director of a successful dot.com start-up in the early 2000s.
Andrew is an advocate of sport and fitness as a gateway to good health. He is passionate about the role of genomics in identifying both the cause of disease and personalized solutions.
Shift towards patient engagement, has generated an unprecedented amount of clinical and commercial data. Applying advanced analytics and artificial intelligence to these data can help pharma companies generate meaningful, actionable insights. In this session, you can learn how pharma marketers and patient engagement managers can use data to engage patients in a multi-channel environment and how to support them during therapy.